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AUDIT                                            Alcohol use disorders identification test  
ADP                                                Adenosine di-phosphate 
ATP                                                 Adenosine tri-phosphate  
BMI                                                 Body Mass Index 
CK                                                   Creatine kinase 
CK- MM                                         CK- Muscle Muscle (muscle type) 
CK- MB                                          CK- Muscle Brain (heart type) 
CK- BB                                           CK- Brain Brain (brain type) 
DBP                                                 Diastolic blood pressure 
EFNS                                               European Federation of Neurological Society 
EMG                                                Electromyography  
ENG                                                Electroneurography  
HyperCKemia                                 Increased serum creatine kinase level 
kDa                                                  kilo Dalton 
MRC-sumscore                               Medical Research Council sumscore 
MRI                                                 Magnetic resonance imaging 
NCS                                                 Nerve conduction studies 
NORIP                                             Nordic Reference Interval Project 
SBP                                                 Systolic blood pressure  
Tromsø 6                                         the 6th survey of The Tromsø Study 
U/L                                                  Units per liter 
ULN                                                Upper limit normal 
URL                                                Upper reference limit 














LIST OF PAPERS 
 
 
I.      Lilleng H, Abeler K, Johnsen SH, Stensland E, Løseth S, Jorde R, Figenschau Y,  
         Lindal S, Wilsgaard T, Bekkelund SI.  
         Variation of serum creatine kinase (CK) levels and prevalence of persistent hyperCKemia  
         in a Norwegian normal population. The Tromsø Study  




II.     Lilleng H, Johnsen SH, Wilsgaard T, Bekkelund SI.  
         Are the currently used reference intervals for creatine kinase (CK) reflecting the general  
         population? The Tromsø Study 




III.   Lilleng H, Abeler K, Johnsen SH, Stensland E, Løseth S, Lindal S, Wilsgaard T,  
         Bekkelund SI.  
         Clinical impact of persistent hyperCKemia in a Norwegian general population.  
         A case control study 








1.1. Mechanism of action and subtypes of CK                                                                
 
CK is a dimeric globular protein consisting of two subunits with a molecular mass of 43 kDa. It 
buffers cellular ATP and ADP concentrations by catalysing the reversible exchange of high-
















 Schematic drawing of the creatine kinase/phosphocreatine (CK/PCr) shuttle in cells 





At least five isoforms of CK exist: three in cytoplasm, CK-MM (muscle type), CK-MB (heart 
type), and CK-BB (brain type) and two in mitochondria [4,5].  
 
 











3. Connected to cellular      






CK isoenzymes can give specific information on injured tissue because of their tissue 
distribution. CK-MM is found in several domains of the myofiber where ATP consumption is 
high, and elevated concentrations in serum due to leakage is considered a marker of muscle 
disease [6]. CK-MB increases in acute myocardial infarction [7], and CK-BB increases in brain 
damage [8].  
CK-MM is specially bound to the myofibrillar M-line structure located in the sarcomere 














Proteins related to muscular dystrophies and localization in the sarcomere. 
Adopted from Brancaccio P. et al. [1] with permission from Oxford University Press, March 
22, 2012 
 
The M-line region appears to be the only myofibrillar structure which connects thick filaments 
(myosin) directly to each other, providing physical stability between thick filaments during 
contraction. The presence of CK-MM suggest that the M-line has a structural and enzymatic 
role to regenerate ATP at sites of high-energy consumption, thus providing myosine with 
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sufficient ATP to work even under strenuous condition [9]. High serum levels of CK depend on 
sarcomeric damage arising either from strenuous exercise or from muscular pathology of 
various mechanisms. About 90% of total CK in normal serum is CK-MM, mainly provided by 
the skeletal muscles. 
 
 
1.2. Causes of increased CK                                                                                    
 
Serum CK activity varies with physiological variables such as age, sex, race, muscle mass and  
physical activity [10-14]. Women have lower CK activity at rest and a slightly increase with 
age, in contrast to men which have a higher CK activity at rest and a slightly decline during life 
[12]. Black men and South Asians usually have higher CK values at rest than Caucasians 
[10,12,15].  
Additionally,  increased serum CK levels (hyperCKemia) is considered an important marker of 
neuromuscular diseases, but CK may also increase in a number of other diseases such as 
cardiac diseases, malignancies, systemic metabolic disorders, thyroid, parathyroid and 
haematological diseases [16-18]. Alcohol, drug abuse and medications (especially statins) are 
also related to hyperCKemia. These make the test less specific, and the investigations of test 
reliability important [11,12,19].  
Symptoms from the musculoskeletal system are a major health problem in many industrialized  
countries [20]. Prevalence of symptoms from skeletal muscle varies from 11% to 50% in 
different population [21-23], but only a minority of patients will expose an underlying muscle 
disease after diagnostic work- up. 
Previous studies focusing on causes of hyperCKemia are mainly based on selected patients 
referred to specialized centres, or retrospective groups of patients. Small samples and lack of 
standardized criteria for identification of groups at risk of underlying neuromuscular disorders 
makes it difficult to extrapolate these results to the general population [24-26].  
Information about the prevalence of marked elevated CK (> 5000 U/L) in unselected, normal 
populations is limited. Knowledge about CK-distribution and prevalence of persistent 
hyperCKemia in the general population may therefore be informative for both clinical and 
scientific purposes. In patients with hyperCKemia, it is also important for the clinician to know 
how CK varies with different physiological conditions. 




1.3. Variation of CK and reference intervals                                                         
 
Recent data suggest that the variation in CK values in normal populations is wider than  
reflected in hospital reference intervals, which may have clinical implications [27,28].  
High CK is common in the general population, supporting the view that defining a cut-off for 
normality should be performed in large general populations, i.e. by using epidemiological 
samples [10,27]. Selecting representative reference individuals is an important and crucial step 
in defining reference values [29,30]. The Nordic Reference Interval Project (NORIP), a 
collaboration of 102 Nordic laboratories, has established biological reference intervals for 25 
frequently requested biochemical quantities [31]. Even though the authors acknowledged  that 
reference individuals should be randomly selected from the normal background population, 
they recruited them from the laboratory staff, their relatives or acquaintances, and among blood 
donors, using a set of inclusion criteria [31,32].  
A fully randomized selection of reference individuals from the entire population is however a 
huge task and not easily carried out for each clinical laboratory due to costs and resources, and 
in practice seldom applied [31,32].  
Properly established ULN CK values reflecting the reference population could reduce the 
burden of false positively CK values. 
 
 
1.4. Guidelines and clinical impact                                                                                                        
 
In routine clinical practice, incidental detection of asymptomatic CK values above the upper 
reference limit (URL, 97.5
th
 percentile) occurs frequently. Values slightly above URL are often 
ignored; presumably reflecting that by definition 2.5% of normal individuals will fall into this 
category, especially in asymptomatic or oligosymptomatic individuals [33]. However, the 
safety of this approach is not assessed in controlled studies.  
Guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia, given by 
EFNS in 2010, recommends investigation with muscle biopsy if serum CK ≥3x normal, if 
myopathic EMG, or if the patient is <25 years of age [33].  
There are no studies addressing the clinical impact and risk factors for asymptomatic, 





2. AIMS OF THE STUDY  
 
- To study variation of serum CK and prevalence of persistent hyperCKemia in a Norwegian             
general population. 
 
- To assess whether the currently used reference intervals for CK are reflecting the general 
population, and to evaluate the need for reference interval adjustments. 
 
- To assess possible risk factors of persistent hyperCKemia in a Norwegian general population, 
and study clinical impact of persistent hyperCKemia. 
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3. SUBJECTS AND METHODS 
 
3.1. Recruitment of participants 
 
All participants were recruited from the 6
th
 survey of The Tromsø Study from October 2007 to  
December 2008.  
The Tromsø Study is a single-centre, population-based prospective study with repeated health 
surveys every 6-7 years, it consists of six surveys (referred to as Tromsø 1–6) that have been 
conducted in the municipality of Tromsø from 1974 to 2008. The first survey was initiated in 
an attempt to help combat the high mortality of cardiovascular diseases in Norway [34]. 
However, during the 37 years since the first examination of the Tromsø Study took place, 
increasing emphasis has been put on other chronic diseases and conditions [34]. Tromsø 4–6 





survey, a total of 10137 women and 9625 men aged 30-87 years were invited (Figure 3).   
 
They were recruited from 4 different groups; 
1)





 a 10% random sample of persons aged 30-39 years, 
3)
 all persons aged 40-42 and 
60-87 years, and 
4)
 a 40% random sample of persons aged 43-59 years.
 
The ethnic composition was 87.3% Norwegians, 1.6% of Sami ethnicity, 1.3% of Finnish 
descent, 2.2% of other ethnicities, and 7.6% without information about ethnicity [34].   
A questionnaire on demographics, education level, general health, familiar illnesses, muscle 
pain, psychiatric illnesses and use of healthcare was enclosed with the letter of invitation. Diet, 
alcohol and smoking habits, use of medication and leisure physical activity were also 
questioned. All attendants underwent physical examinations which included measurement of 
height, weight, waist and hip circumference, blood pressure and collection of blood samples. 
CK was analyzed in 12828 participants, 64.9% of those eligible (Visit 1, Figure 3).  
According to the protocol, persons with CK values > 5000 U/L were especially monitored 
during the study and promptly remitted to the Department of Neurology and Neurophysiology, 





Invited persons to 
The 6
th
 Tromsø Study 
n = 19762 
 
Available for CK 
analysis  
n = 12828 (65%)  
(age 30-87 years) 
Non responders  
3207 women    3571 men 
 
No blood samples  
96 women         60 men 
Fig. 3. Flow chart defining the study population 
HyperCKemia 
n = 686 
295 women        391 men 
(43%)                (57%) 
Persistent hyperCKemia 
(30.1%)  
            n = 169 
89 women           80 men 
Control CK test (n=562) 
after 3 days refraining 
from exercise, alcohol, or 
any muscular damage 
Normalized 
CK value (69.9%) 
n = 393 
160 women           233 men  
No control test, emigrants 
and dead 
n = 124 
46 women              78 men 
First CK-test 
Double blind case-control study 
Case n = 120  Control  n = 130 





Recruitment of participants, Paper I  
 
All 686 persons with elevated CK values from Visit 1 were offered a standardized control test 3 
days after refraining from use of alcohol, leisure physical activity, muscular training, 
physiotherapy, acupuncture or any muscular damage. The control procedure was described in 
writing. If the control CK value was above the upper reference limit, the person was classified 
as having persistent hyperCKemia. In all, 562 persons had a control test and 169 had persistent 
hyperCKemia. 
 
Recruitment of participants, Paper II  
 
A total of 5924 (46.2%) individuals from Visit 1 with one or more potential causes of 
hyperCKemia were excluded as reference individuals; statin users (n=1846), hypothyroidism 
(n=1093), current kidney disease (n=525), hard leisure physical exercise defined as high 
activity (sweating or out of breath) at least 1 h/week (n=1361), and high alcohol consumption 
defined as drinking alcohol at least 2 times/week (n=2774).  
The remaining 6904 individuals (53.8%) were defined as reference individuals. 
Data from the standardized CK controls (562 out of 686 individuals with incidentally elevated 
CK values, shown in Figure 3) were included after first excluding 143 individuals owing to use 
of statins, reporting hypothyroidism or kidney disease. Seventy-two individuals performed hard 
leisure physical exercise and 65 reported high alcohol consumption; these 137 were all 
included as reference individuals as the standardized CK control analysis adjusted for these 
conditions. 
Visual inspection of the histograms revealed one man with a CK value 7888 U/L. After  
applying the Dixon range statistics ( “one-third” rule) suggested by Reed et al. this person 
was excluded as an outlier [35].  
 
Recruitment of participants, Paper III   
 
All persons aged 30–80 years with persistent hyperCKemia from visit 1, together with sex-and 
age-matched controls (randomly within 5 years groups) with CK values in the 30-50 percentile 
of reference CK (Figure 3), were invited to participate in a case-control study in order to 
compare clinical characteristics, neurological findings, and distribution of variables associated 
with hyperCKemia.  
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Also the controls were instructed to restrain from use of alcohol and muscular load, leisure 
physical activity, muscular training, physiotherapy, acupuncture or any muscular damage 3 days 
ahead of a control CK blood sample before they were finally included.  
Both the participants and the investigators were blinded to CK values to avoid selection and  
observation bias. The double blinding procedure was organized by a research consultant (AKK)  





In paper III, eligible cases and controls underwent a standardized interview supplied by 
information from the hospital medical record. A complete clinical neurological examination 
supplied by a neurophysiological examination were performed by HL and co-workers (SIB, 
SHJ, ES, KA and SL), all experienced neurologists at the Department of Neurology and 
Neurophysiology. Demographic variables included age, sex, occupation and ethnicity 
(“Caucasian”, “African origin” or “Other”).  
Duration of current medication was noted. All participants were asked if they or their first or 
second degree relatives had a known muscle disease diagnosis. Previous or current peripheral 
nerve disease or other diseases known to cause hyperCKemia (eg. heart disease, cancer illness, 
systemic metabolic disease, haematological disease, thyroid and parathyroid diseases, liver and 
kidney diseases) were recorded [13,14,33].  
Any history of malignant hyperthermia or malignant neuroleptic syndrome and 
myoglobulinuria was registered [13,14,33].  
Presence of muscle pain, stiffness or cramps last two weeks, and any muscle trauma, seizures, 
fever cramps or any muscular injections last four weeks were noted. 
The participants were asked to stipulate their leisure physical activity the last year and the last 
month.  “Mild activity” was defined as activity without sweating or breathlessness ≥ 3 hours 
per week last month, and “Strenuous activity” was defined as activity with presence of 
sweating or breathlessness ≥3 hours per week last month.  
The alcohol use disorders identification test (AUDIT) was used to evaluate alcohol 
consumption [36]. High consumption was defined as AUDIT ≥11.  
Blood pressure was measured in supine position with a digital blood pressure monitor (A&D 
Model UA-779; A&D Instruments Ltd, Abingdon, Oxon, UK). 
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Weight was measured by a validated digital weight (Weighingblock VB3-200-EC, Class III; 
Vetek, Sweden). Medical Research Council sumscore (MRC-sumscore) was used for manual 
muscle strength testing [37].  
To measure muscle strength we examined knee extension of the dominant leg (peak torque, 
Nm) using a Cybex NORM dynamometer (CSMI, Norwood, MA, USA). After a short, 
standardized warm up, the participants had an introductional test- examine of 3 subsequent 
knee extension and flexions. Then the formal 3 tests were performed, and the average Nm 
recorded. 
The handgrip strength (kPa) was measured on the dominant hand using a Martin vigorimeter, 
(Elmed Inc., Addison, IL, USA) [38]. The participants could choose between 3 different sizes 
of handcuffs, i.e. finding the one fitting each person’s hand size. The test was done recording 
the highest of 3 attempts.  
Nerve conduction studies (NCS) and electromyography (EMG) were performed unilaterally 
(dominant side) in all participants using Keypoint equipment (Medtronic, Copenhagen). The 
protocol included motor NCS of the median, ulnar and tibial nerves and sensory NCS of the 
median, ulnar and sural nerves. EMG investigation was performed in the extensor digitorum 
communis, deltoid, vastus lateralis and tibialis anterior muscles.  
Motor- or sensorimotor axonal neuropathy was considered a possible cause of hyperCKemia if 
EMG showed a neurogenic pattern with denervation activity in two or more muscles (of which 
one was the tibialis anterior muscle), with or without NCS abnormalities in two or more nerves 




All blood samples were analyzed at the University Hospital of North Norway. CK was 
measured by photometry using an enzymatic method (CK-NAC, Roche Diagnostics®, 
Mannheim, Germany). The samples were consecutively analyzed in an automated clinical 
chemistry analyzer (Modular P, Roche) within 6 hours from withdrawal. The analytical 
coefficient of variation (CVa) was ≤1.6%, and the reference interval for this method was that 
elaborated by the Nordic Reference Interval Project (NORIP); women aged ≥18 years, 35 – 210 
U/L, men aged 18 – 50 years, 50 – 400 U/L, and men ≥ 50 years, 40 – 280 U/L [31].  
When the CK level in a sample was beyond the upper limit, the sample was diluted according 
to recommendation given by the manufacturer. 
The laboratory participates in LABQUALITY, a quality control system including about one 
hundred laboratories, mainly in the Nordic countries. The Department of Laboratory Medicine 
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receives control samples four times annually, and has always had results within the analytical 




SPSS version 16.0 for Windows (Inc., Chicago, IL) was used for statistical analyses in all 
papers, in addition the SAS System version 9.2 (SAS Institute, Inc., Cary, North Carolina) was 
used in paper II. Descriptive data were presented as median (range) or mean (standard 
deviation), and a two-tailed p value <0.05 was considered statistically significant. 
 
Paper I  
 
Proportions of hyperCKemia were calculated in 10-year age groups for women and men. 
Wilcoxons signed rank test was used to compare differences in CK levels between the initial 
CK test and the control test (within group difference), and Mann-Whitney test to compare the 
CK levels between statin and non-statin users (between group differences). Chi square test was 
used to compare the proportion of CK-normalization between statin- and non-statin users. 
 
Paper II  
 
In order to reduce the skewness and kurtosis of the data, CK were raised to the power of -0.1 as 
the most optimal power transformation (using Box-Cox transformations). Fractional 
polynomials were fitted in a linear regression model to find the best relationship between the 
transformed CK and age. The powers for fractional polynomials were chosen from a set φ = 
(−2,−1,−1/2, 0, 1/2, 1, 2, 3) [39]. The best fitting fractional polynomials was of degree 2 with 
powers -2 and 3 in men and -0.5 and 1 in women. 
Age-related reference centiles were constructed using the absolute residuals approach proposed 




Figure 4 Distribution of CK in men (upper) and women (lower) by age (CK values > 800 U/L 
are not shown) 
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Chi square test for cross tables was used to test differences between CK-quartiles, and to test 
for linear trend in normalization after control analysis (Figure 5).  










































Figure 5 Pattern of normalization of elevated CK after control analysis in quartiles (Q1 – Q4) 
Q1; Women: 210-230 U/L, men ≥ 50 years: 280-312 U/L and men < 50 years: 408-458 U/L 
Q2; Women: 231-262 U/L, men ≥ 50 years: 315-358 U/L and men < 50 years: 466-628 U/L 
Q3; Women: 264 -324 U/L, men ≥ 50 years: 361-448 U/L and men < 50 years: 668-1028 U/L 
Q4; Women: 327-3046 U/L, men ≥ 50 years: 448-2452 U/L and men < 50 years: 1050-15941U/L 
 
After deletion of individuals with potential causes of hyperCKemia and one outlier and 
including the data from individuals with completed standardized control CK analysis, we non-
parametrically calculated CK reference intervals according to the 2.5 – 97.5 percentile [41], and 







Paper III  
 
Unpaired t-test and Chi square test for cross tables was used to test differences between cases 




The project was approved by The Regional Ethical Committee for research and the Norwegian 
Data Inspectorate. (Approval number: REK NORD 11/2008). Written consent was obtained 


























In paper I we assessed the prevalence of hyperCKemia, defined as persistent CK values ≥ 210 
U/L in women, ≥ 400 U/L in men < 50 years and ≥ 280 U/L in men ≥ 50 years (reference 
values according to the Nordic Reference Interval Project).  
Blood samples were obtained from 12 828 participants. We identified 686 (5.3%) individuals 
with incidentally elevated CK. After a standardized control test, 169 persons (1.3%) had 
persistent hyperCKemia, i.e. 69.9% normalization. Use of statins or other risk factors of 
hyperCKemia were detected in 78 individuals (46.2%), giving a prevalence of “idiopathic 
hyperCKemia” of 0.71%. CK variation was highest in younger men, and in females between 
60-69 years.  
In conclusion, this study identified persistent hyperCKemia in 1.3% of the normal population, 
and demonstrates the importance of performing controlled CK analyses, also in those with 




This study compared creatine kinase (CK) reference intervals calculated from the Tromsø  
Study population with those elaborated by the Nordic Reference Interval Project (NORIP). It  
also assessed the pattern of CK-normalization after standardized control analyses. New upper  
reference limits (URL) CK values were calculated after exclusion of individuals with risk of  
hyperCKemia and including individuals with incidentally detected hyperCKemia after they  
had completed a standardized control analysis. After exclusion of 5924 individuals with  
possible causes of hyperCKemia, CK samples were analyzed in 6904 individuals. URL was  
defined as the 97.5 percentile. 
In the reference sample population the 2.5 – 97.5 CK percentile interval (90 % confidence  
interval, CI) in women was 37 (36 – 38) U/L – 207 (197 – 212) U/L, compared to  
NORIP reference interval 35 (31 – 35) U/L – 210 (180 – 233) U/L. 
The corresponding finding in men < 50 years of age was 57 (54 – 61) U/L – 395 (362 –  
416) U/L, compared to NORIP reference interval 50 (45 – 54) U/L – 400 (351 – 487) U/L. In  
men ≥ 50 years the 2.5 – 97.5 CK percentile interval was 47 (44 – 51) U/L – 340 (287 –  
372) U/L, compared to NORIP reference interval 40 (36 – 46) U/L – 280 (252 – 415) U/L.  
In individuals with elevated CK, normalization grade after control analysis was inversely  
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correlated to the CK level (p < 0.04 for linear trend). 
In conclusion, URL CK values in women and in men < 50 years of age were in accordance  
with URL CK values given by the NORIP. In men ≥ 50 years, we found a higher URL  
suggesting an upward adjustment of URL in this age group. 
     
Paper III  
 
In this case-control study we assessed the clinical impact of persistent hyperCKemia in a 
Norwegian general population. HyperCKemia was defined according to the NORIP- references.  
We compared the frequency of muscular symptoms and function, neuromuscular diseases and 
risk factors between 120 cases with persistent hyperCKemia and 130 age- and sex-matched 
controls with normal CK values, all recruited from the single-centre, population-based 
prospective Tromsø Study. 
The participants underwent a standardized interview assessing muscle symptoms, physical 
activity, use of statins and presence of other CK risk factors, prior to clinical neurological and 
neurophysiological examination. Knee extensor muscle strength (Cybex NORM dynamometer) 
and dominant hand grip strength (Martin Vigorimeter) were assessed. 
A total of 85 cases (71%) reported either muscle pain, muscle stiffness or cramps, compared to 
70 controls (54%) (p = 0.017). There were no differences in muscle strength between the 
groups.  
In men, weight, Body Mass Index and muscle symptoms were significantly higher in the group 
with persistent hyperCKemia. In women, no differences between the groups were detected.  
Frequency of statin users was similar in cases and controls. We diagnosed 3 women with 
previously unknown myopathy, all in the group with persistent hyperCKemia.  
This study support that CK may be used as a marker of muscular symptoms in the general 
population, and support the view of recent publicised EFNS guidelines on diagnostic approach 








5. DISCUSSION            
 
5.1. Methodological considerations   
          
5.1.1 Study design 
 
The data in this project is derived from Tromsø 6, a repeated epidemiological, cross sectional 
study, organized by Institute of Community Medicine, University of Tromsø. 
A cross-sectional study involve data collected at a defined time or over a short period, and is 
suitable when assessing prevalence and outcome, identifying risk factors and generating 
hypotheses for future research.  
A limitation is that it may be difficult to make causal inferences, i.e. it is not possible to 
distinguish whether the exposure preceded or followed the disease. The observations should 
therefore not be overextended. Another limitation is that the situation may provide differing 
results if another time-frame had been chosen.  
The major strengths of this study are the large sample size, high participation rate and the 
double blind design in the case control part. 
 
One of the most important drawbacks in case-control studies in general relates to recall bias, 
i.e. the difficulty of obtaining reliable information about an individual’s exposure status over 
time.  
In our study, variables such as self-reported leisure physical activity the recent month and year, 
and presence of muscular symptoms (pain, stiffness and cramps), etc. might be biased.   
 
Physical activity is known to elevate serum CK. We had no information of the participant’s 
physical activity prior to the first CK blood test (Visit 1), and could therefore not be certain of 
the validity of these data. A standardized control test 3 days after restraining from use of 
alcohol and muscular load, leisure physical activity, muscular training, physiotherapy, 
acupuncture or any muscular damage provided better data quality. 
Three days has been used in a prior analogous study [27], and was chosen since increased CK 
levels after eccentric exercise are associated with muscle injury, with a pronounced increase 
between 2 and 7 days after exercise [42]. Additionally, we assumed that 3 days instead of 7 
days would increase participants’ compliance, i.e. reduce the risk of drop-outs not completing 
the control test.  However, 3 days may be too short an interval since the half-life of CK is 
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considered to be more than 7 days [42,43]. The degree of normalization can therefore be higher 
than observed.  
We clinically assessed muscle symptoms and muscle strength, and used EMG to diagnose 
neuropathy and myopathy. MRI imaging of affected muscles, muscle biopsy and genetic testing 
could have added valuable information about the correlation between hyperCKemia and muscle 
function and muscle diseases. 
   
                   
5.1.2 Internal validity (selection- and observation bias, information bias, confounding) 
 
Selection- and observation bias 
 
A participations rate of 65% is an acceptable response-rate in a large epidemiological study; in 
addition, there were no predefined selection criteria for invitation other than birth year and 
being a resident of the municipality of Tromsø. Except from age and gender, we have no 
information about the 35% non-responders, which may cause selection bias. As Tromsø 6 only 
invited participants in the age group 30–87 years, we have no data from participants younger 
than 30 years.  
Furthermore, the participation rate was highest in the age group 60–69 years, and lowest among 
the youngest and the elderly. This is especially of concern for the youngest men, where the CK 
variation was greatest and the attendance lowest.  
 
By keeping participants unaware of their CK values throughout the study period, selection bias 
is further minimized. To reduce the risk of different clinical approach to cases and controls 
(observation bias), the investigators also were unaware of the participants CK values (“double 
blinded design”). The blinding procedure was performed without exceptions throughout the 
study. 
 
The 49 non responders (29%) with persistent hyperCKemia not included in the case control 
study may cause selection bias. A separate analysis of the non-responder’s questionnaires from 
Tromsø 6 (Visit 1, Figure1) revealed however no significant differences regarding sex, age, 
median CK, use of statins and use of thyroxine, compared to the 120 cases included. 
Approximately 75% of the participants were clinical investigated by HL, the remaining 25% 
were examined by co-workers (SIB, SHJ and ES). A great variation in clinical judgement could 
cause observation bias, but we have though not done an interobserver reliability test. This is 
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especially relevant for the tests where clinical judgement is prominent; muscle strength testing, 
MRC sum score and clinical neurological investigation. 
Another limitation is the lack of neurophysiological consensus concerning definition of  
neuropathy and myopathy. There is neither consensus regarding which subtypes of neuropathy  
most inclined to cause CK elevation.  
In this study motor- or sensorimotor axonal neuropathy was considered a possible cause of  
hyperCKemia if EMG showed a neurogenic pattern with denervation activity in two or more  
muscles (of which one was the tibialis anterior muscle), with or without NCS abnormalities in 
two or  more nerves (not including carpal tunnel syndrome). 
 
Information bias  
 
Information bias occurs when measurement of either the exposure or the outcome variables is 
systematically inaccurate. This problem has been addressed in the Tromsø study in general by 
having test personnel that are not directly involved in the scientific project and thereby not 
biased by scientific hypothesis in their measurement. In addition, standard operational 
procedures and standard protocols contributed to minimize errors. 
In paper I information on use of medication and risk factors for hyperCKemia was obtained 
from self-administrated questionnaires. Such information is likely to be inaccurate and a source 




A confounder is an independent risk factor for the outcome variable that is also associated with  
one or more of the exposure variables of interest. Confounding could lead to under- or  
overestimation of the association studied.  
 
We tried to reduce the effect of confounding by doing age- and gender specific analyses. In  
addition, as use of statins is considered a potential cause of hyperCKemia [46-49], we also did 
separate analysis in statin user and none users.  
Except from more muscle symptoms, the only differences we could detect were higher weight 
and BMI in male cases with persistent hyperCKemia. This could theoretically be explained by 
less leisure physical activity, but there were no significant difference in reported physical 
activity among the male study participants. A bigger muscle mass in men with persistent 
hyperCKemia may also explain this difference. Although we lack a distinct clinical measure of 
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muscle mass, Waist- Hip ratio (WHR) could help differentiate abdominal (central) adiposity 
from muscle mass, though a crude and non- evidence based estimation. There was no 
difference in WHR or difference in muscle strength for dominant handgrip or knee extension in 
males. This may indicate that muscle mass probably was relatively equal.  
Nevertheless, weight and BMI may be considered as potential confounders in future CK-  
studies. 
 
5.1.3 External validity 
 
This refers to the generalizability of results and applicability to other populations. Selection 
criteria for participation in Tromsø 6 were age and residency in Tromsø, and the Population 
Registry of Norway was the source for the invitations. The risk factor levels of the Tromsø 
population are comparable to other Western populations; however, generalizability could be 
restricted by ethnicity. In Tromsø 6, >90% reported to be Caucasians, and in the case control 
study all individuals were Caucasians.           
 
 
5.2. Discussion of main results and clinical implications 
 
In clinical practice a relative frequent challenge is how to deal with individuals with elevated 
CK, with or without muscular symptoms. Incidentally detected elevated CK values are 
common, the present study has demonstrated the prevalence to be 5.3% in the general 
population. In 2011 the Department of Medical Biochemistry, University Hospital of North 
Norway in Tromsø analyzed 26.198 CK blood samples (personal announcement), illustrating 
the extent of the problem. 
The importance of doing control CK tests was underlined in paper I as we calculated the  
prevalence of persistent hyperCKemia after a standardized control test to be 1.3% in both  
genders. An approximately 70% normalization rate was seen also in individuals using statins,  
emphasizing the importance of doing control test also in individuals with an apparently known  
risk factors or explanation of elevated CK.  This could have both clinical and scientific  
implications for statin users, i.e. avoiding unnecessary withdrawal of statins in patients with  
moderately elevated CK, preventing potentially misclassification and exclusion of patients with  
elevated CK before randomization into statin trials [27].  
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The prevalence of hyperCKemia is highly dependent of which level of URL CK that is used. 
Our estimations of hyperCKemia prevalence’s were based on URL given by the NORIP [31].  
The importance of properly established URL CK values was demonstrated by Brewster  
et al as the variation in CK activity within the population is wide, and relatively high values  
occur frequently [27]. In our study population, we identified 4 men with CK values  
above 5000 U/L (15941, 12022, 8079 and 5660 U/L). All 4 normalized after standardized  
control tests, and clinical neurological follow up examinations were normal. 
In paper II we compared URL given by NORIP to CK values calculated in our general 
population [41]. URL CK values in women and in men <50 years of age were in  
accordance with the NORIP criteria. In men ≥50 years we found a higher URL, suggesting an  
upward adjustment in this age group. This URL found in men ≥50 years is probably more 
clinical representative compared to the NORIP result, as our calculation is based on five times 
more reference individuals, all recruited from a general population.  
          
The effect on neuromuscular diagnosis after raising the URL from 174 U/L to 322 U/L in men, 
and from 140 U/L to 201 U/L in women were evaluated by Nardin et al [50]. The higher URL 
resulted in a false negative CK of clinical significance in 7 of 94 subjects (7.4%). The clinical 
impact of loss in sensitivity was considered small, and reduced unnecessary referrals and 
invasive testing in patients with asymptomatic CK elevations [50].  
In paper III we identified only 3 women with previously unknown myopathy among 120 
persons with persistent hyperCKemia, recruited from a background population of 12 828 
people. Men with hyperCKemia had more muscle symptoms; otherwise we could not 
demonstrate other clinical relevant differences between individuals with persistent 
hyperCKemia and the control group. A total of 116 individuals (97%) with persistent 
hyperCKemia had CK <3x normal. Our findings indicate that the potential loss of sensitivity 
for the diagnosis of myopathy is small when applying the CK ≥3x normal as a diagnostic limit 
for further investigation, and these results are in accordance with guidelines on the diagnostic 
approach to pauci- or asymptomatic hyperCKemia given by EFNS in 2010 [33].  
            
In paper I, based on questionnaires, we found a possible cause or risk factor for persistent  
hyperCKemia in 46% of the subjects. Use of statins was the most common reported risk factor. 
The precise mechanisms underlying statin-induced myotoxicity remain unclear. Hypothesized  
explanations to the increased cytotoxicity are deficiency in chloride channel activation and  
increased intracellular calcium concentration causing destabilization of the cell membrane, as  
well as interruption of the glycoprotein synthesis [51].  
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However, in the case-control study (paper III), we were not able to demonstrate any difference 
in prevalence or duration of statin treatment between cases and controls. We could neither 
demonstrate more muscle symptoms nor reduced muscle power among statin users. Neither 
was the CK level in individuals with persistent hyperCKemia related to statin use. However, as 
the overall numbers included in the case-control study were small, the statistical power to do 
subgroup analyses was reduced, and this may explain the negative findings.  
            
Based on observations from black and multiethnic populations, it has been hypothesized     
that a genetically high tissue CK activity may be an independent factor responsible for primary  
hypertension [52-54]. It has further been demonstrated that low CK levels are associated with 
lower blood pressure and an increased prevalence of fainting [55].  
In a recent paper from our study group we found that CK was associated with blood pressure  
[56]. The association was independent of antihypertensive medication, and no  
difference in CK level was found between those with controlled and uncontrolled hypertension. 
The effect of CK was present after adjustment for age, sex, BMI, s-glucose, s-creatinine,  
physical activity and alcohol consumption [56-59]. We do not know whether CK activity is a 
causal factor involved in the pathogenesis of hypertension or a secondary metabolite caused by 
impaired renal function or differences in muscle fiber properties. An important assumption for 
the hypothesis is that CK should be increased, not only in striated muscle but also in smooth 
muscle and cardiac muscle in hypertensive persons. At present, there is no evidence of this in 
humans. It would also be of great interest to know whether CK falls when blood pressure is 
lowered and whether high CK is related to a more therapy-resistant hypertension.  
Future studies should focus on these questions. 
In the case-control study (paper III) we found higher systolic and diastolic blood pressure in 
both men and women with persistent hyperCKemia compared to controls, but the differences 














This study identified incidentally elevated CK in 5.3% of the normal population, and a  
prevalence of persistent hyperCKemia of 1.3% in both genders, based on NORIP –reference  
intervals. Use of statins or other risk factors of hyperCKemia were detected in 46%, giving a  
prevalence of “idiopathic hyperCKemia” of 0.7%. 
Nearly 70% of all cases with incidentally elevated CK normalized after refraining from use of  
alcohol and muscular load, leisure physical activity, muscular training, physiotherapy,  
acupuncture or any muscular damage 3 days ahead of a control CK blood sample.  
The normalization grade after control analysis was inversely correlated to the CK level. This  
emphasizes the clinical importance of doing a standardized control blood test before  
diagnosing persistent hyperCKemia, also in those with identified risk factors. 
After comparing CK- reference intervals calculated from the Tromsø Study population with  
those elaborated by the NORIP, we have demonstrated that URL CK values in women and in 
men <50 years of age were in accordance with URL CK values given by the NORIP. 
In men ≥50 years, we found a higher URL, suggesting an upward adjustment of URL in this 
age group. 
The frequency of muscular symptoms and function, neuromuscular diseases and risk factors in   
120 cases with persistent hyperCKemia compared to 130 age- and sex-matched controls with  
normal CK values revealed that men with hyperCKemia had more muscle symptoms, higher 
weight and higher BMI.  
This support that CK may be used as a marker of muscular symptoms in the general  
population. Otherwise we could not demonstrate other clinical relevant differences between  
cases and controls, indicating that our findings imply little clinical impact of incidentally  














The double blind case-control study identified only 3 women with previously unknown  
myopathy, all in the group with persistent hyperCKemia. The myopathy diagnoses were based  
entirely on EMG investigation, although this assessment ideally should have been completed  
with muscle biopsy [60,61]. Our next step is to do muscle biopsy in all participants, to assess 
potential biological/morphological alterations in the skeletal muscles, and thereby increase the 
sensitivity of the myopathy diagnosis.  
In addition, to examine the correlation between morphological changes in skeletal muscles and  
muscle function (muscle power), as well as the correlation between morphological changes and  
muscular symptoms. 
Use of statins is considered a potential cause of hyperCKemia [46]. Statin induced myopathy 
occurs in 0.1–0.2% of patients receiving statins in clinical trials, and in 5–10% in clinical 
practice [47-49].  
In our study, we were not able to demonstrate any difference in prevalence of statin use or  
duration of treatment between cases and controls. Neither was the CK level in individuals with  
persistent hyperCKemia related to statin use. We could neither demonstrate more muscle  
symptoms nor reduced muscle power among statin users. 
Doing muscle biopsy in all individuals with persistent hyperCKemia using statins or not could  




A genetic blood sample screening of individuals with persistent hyperCKemia recruited from a  
normal population is to our knowledge not previously done.  
Muscle biopsy and a complementary genetic screening are considered the most comprehensive  
tools in present diagnostic work up of muscular diseases. 
We have planned to do a simplified genetic testing (preferably a commercially available  








In the case-control study participants with persistent hyperCKemia had higher systolic and 
diastolic blood pressure compared to controls, but the differences did not reach statistical 
significance. This is most likely due to the limited numbers included in the study, and a future 
CK trial should try to include more participants. 





There are a limited number of follow up studies of individuals with persistent hyperCKemia   
[62], and present knowledge of long term effects of hyperCKemia is sparse. Our  
study cohort is suitable to reinvestigate after 5-10 years. Such a follow up study could add  
valuable data about the impact of long term effects of moderately elevated CK on muscular  
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